The CA 125 gene: A newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure

Tumor Biology

Volumn 23, Issue 3, 2002, Pages 154-169

  O'Brien, Timothy J ^a,c   Beard, John B ^a   Underwood, Lowell J ^a   Shigemasa, Kazushi ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

CA 125 clone; Glycoprotein, extracellular; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; GLYCOPROTEIN; TUMOR MARKER; MESSENGER RNA;

AMINO TERMINAL SEQUENCE; ARTICLE; CA 125 GENE; CONTROLLED STUDY; CYSTADENOCARCINOMA; EMBRYO DEVELOPMENT; EPITHELIUM; EXTRACELLULAR SPACE; GENE; HUMAN; HUMAN TISSUE; METASTASIS; MUCINOUS CARCINOMA; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; AMINO ACID SEQUENCE; CHEMISTRY; FEMALE; GENETICS; METABOLISM; MOLECULAR GENETICS; OVARY TUMOR; POLYMERASE CHAIN REACTION; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SEQUENCE; CA-125 ANTIGEN; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE, TERTIARY; RNA, MESSENGER;

EID: 0036560755     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064032     Document Type: Article

References (10)

1. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RC, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-1337.
2. Yin TWT, Lloyd KO: Molecular cloning of the CA125 ovarian cancer antigen. Identification as a new mucin (MUC16). J Biol Chem 2001;276:27371-27375.
3. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L: The CA125 gene: An extracellular superstructure dominated by repeat sequences. Tumor Biol 2001;22:348-366.
4. Hovig E, Rye PD, Warren DJ, Nustad K: CA 125: The end of the beginning. Tumor Biol 2001;22:345-347.
5. Benedet JL, Bender H, Jones H 3rd, Ngan HYS, Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-262.
6. Scully RE: Tumors of the Ovary and Maldeveloped Gonads, ser 2. Washington, Armed Forces Institute of Pathology, 1979. pp 53-151.
7. Shigemasa K, Hu C, West CM, Clarke J, Parham GP, Parmley TH, Korourian S, Baker VV, O'Brien TJ: P16 overexpression: A potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig 1997;4:95-102.
8. Shigemasa K, Hu C, West CM, Moon SH, Parham GP, Parmley TH, Korourian S, Baker VV, O'Brien TJ: P21: A monitor of p53 dysfunction in ovarian neoplasm. Int J Gynecol Cancer 1997;7:296-303.
9. Shigemasa K, Tammoto H, Parham GP, Parmley TH, Ohama K, O'Brien TJ: Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig 1999;6:102-108.
10. Nustad K, Onsrud M, Jansson B, Warren D: CA125 - Epitopes and molecular size. Int J Biol Markers 1998;13/4:196-199.